



**Tatva Chintan Pharma Chem Limited**  
(Formerly known as Tatva Chintan Pharma Chem Private Limited)  
(CIN:L24232GJ1996PLC029894)



Date: 25 July 2022

Ref No: TCPCL/SEC/2022-23/00036

To,  
**The General Manager,**  
**Corporate relationship department,**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001  
**Scrip Code: 543321**

**The Manager,**  
**Listing department,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla, Complex Bandra(E),  
Mumbai-400 051  
**Scrip Symbol: TATVA**

**Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022.

The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022.


Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.

The above information shall be made available on the website of the Company at [www.tatvachintan.com](http://www.tatvachintan.com).

The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M.

Kindly take above intimation on your record and oblige.

Thanking You,  
Your Faithfully,  
**For Tatva Chintan Pharma Chem Limited**

  
**Ishwar Nayi**  
**Company Secretary and Compliance Officer**  
**M. No.: A37444**



**Encl: As Above**

**Registered Office and Factory :** Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

**Dahej SEZ Unit :** Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

**Corporate Office and R & D Center (DSIR Approved) :** Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

**Telephone No. :** +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** [cs@tatvachintan.com](mailto:cs@tatvachintan.com) **Website :** [www.tatvachintan.com](http://www.tatvachintan.com)

V - 00288

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Tatva Chintan Pharma Chem Limited ("Holding Company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2022 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended for the purpose of filing it with the BSE Limited and the National Stock Exchange of India Limited.
2. This Statement, which is the responsibility of the Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the following entities:
  - a) Tatva Chintan Pharma Chem Limited – the Holding Company
  - b) Tatva Chintan USA Inc. – Wholly Owned Subsidiary
  - c) Tatva Chintan Europe B.V. – Wholly Owned Subsidiary
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes results for the quarter ended 31<sup>st</sup> March, 2022 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to third quarter of the financial year which were subjected to limited review by us.

Our conclusion on the Statement is not modified in respect of this matter.



8. Our report is intended solely for use of the management for its onward submission to the BSE Limited and National Stock Exchange of India Limited in connection with the listing of equity shares of the Holding Company as mentioned in Para 1 above. As a result, the Statement may not be suitable for another purpose. Our report should not be used, referred to or distributed for any other purpose except with our prior consent in writing.

For NDJ & Co.,  
Chartered Accountants  
Firm's Registration Number: 136345W



CA Mitali Mehta  
Partner



Membership No. 143475  
UDIN No : 22143475ANOAQU9421

Date: 25<sup>th</sup> July 2022  
Place: Surat



## Tatva Chintan Pharma Chem Limited

(Formerly known as Tatva Chintan Pharma Chem Private Limited)

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat, India – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

### CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022

(Currency: Indian Rupees in Million, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2022 (Unaudited)	31.03.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
	<b>Income</b>				
1	Revenue from operations	884.02	985.31	1,068.32	4,336.47
2	Other income	18.29	3.54	13.22	88.94
3	<b>Total income (1+2)</b>	<b>902.31</b>	<b>988.85</b>	<b>1,081.54</b>	<b>4,425.41</b>
	<b>Expenses</b>				
	a) Cost of materials consumed	512.65	627.61	516.60	2,544.94
	b) Purchases of stock-in-trade	11.37	7.31	12.03	36.79
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(125.52)	(237.48)	3.43	(635.34)
	d) Employee benefits expense	85.81	82.49	70.37	308.14
	e) Finance costs	10.17	11.81	14.39	48.32
	f) Depreciation and amortisation expenses	23.33	21.48	18.98	81.80
	g) Other expenses	247.55	285.87	203.13	999.55
4	<b>Total expenses</b>	<b>765.36</b>	<b>799.09</b>	<b>838.93</b>	<b>3,384.20</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>136.95</b>	<b>189.76</b>	<b>242.61</b>	<b>1,041.21</b>
6	Exceptional items	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>136.95</b>	<b>189.76</b>	<b>242.61</b>	<b>1,041.21</b>
	<b>Tax expenses/(benefits)</b>				
	Current tax	35.25	38.90	42.62	189.76
	Deferred tax	3.73	(24.23)	(31.47)	(107.29)
8	<b>Total tax expenses</b>	<b>38.98</b>	<b>14.67</b>	<b>11.15</b>	<b>82.47</b>
9	<b>Profit for the period/year (7-8)</b>	<b>97.97</b>	<b>175.09</b>	<b>231.46</b>	<b>958.74</b>
	<b>Other comprehensive income/(expense)</b>				
	Items that will not be reclassified to profit or loss	(0.61)	(0.50)	(1.49)	(2.05)
	Income tax relating to items that will not be reclassified to profit or loss	0.18	0.17	0.41	0.60
	Items that will be reclassified to profit or loss	1.46	0.00	0.82	2.98
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
10	<b>Other comprehensive income/(expense) for the period/year, net of tax</b>	<b>1.03</b>	<b>(0.33)</b>	<b>(0.26)</b>	<b>1.53</b>
11	<b>Total comprehensive income for the period/year (9+10)</b>	<b>99.00</b>	<b>174.76</b>	<b>231.20</b>	<b>960.27</b>
12	<b>Profit for the period/year attributable to:</b>				
	- Owners of the parent	97.97	175.09	231.46	958.74
	- Non controlling interests	-	-	-	-
		<b>97.97</b>	<b>175.09</b>	<b>231.46</b>	<b>958.74</b>
13	<b>Other comprehensive income/(expense) for the period/year attributable to:</b>				
	- Owners of the parent	1.03	(0.33)	(0.26)	1.53
	- Non controlling interests	-	-	-	-
		<b>1.03</b>	<b>(0.33)</b>	<b>(0.26)</b>	<b>1.53</b>
14	<b>Total comprehensive income for the period/year attributable to:</b>				
	- Owners of the parent	99.00	174.76	231.20	960.27
	- Non controlling interests	-	-	-	-
		<b>99.00</b>	<b>174.76</b>	<b>231.20</b>	<b>960.27</b>
15	<b>Earnings per share (Face value of Rs 10/- each)</b> (not annualised)				
	- Basic	4.42	7.90	11.52	44.59
	- Diluted	4.42	7.90	11.52	44.59
16	<b>Paid - up equity share capital (Face value of Rs 10/- each)</b>	<b>221.65</b>	<b>221.65</b>	<b>200.88</b>	<b>221.65</b>
17	<b>Other equity excluding revaluation reserve</b>				<b>4,509.24</b>

See accompanying notes to the consolidated financial results.

*Chintan Shah*



*Meheta Nitali*



**Tatva Chintan Pharma Chem Limited**  
(Formerly known as Tatva Chintan Pharma Chem Private Limited)  
CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat, India – 393 002  
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

**NOTES TO CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022**

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, this Statement of Consolidated Financial Results for the quarter ended 30 June 2022 ("Consolidated Financial Results") of Tatva Chintan Pharma Chem Limited ("Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 25 July 2022, which has been subjected to limited review by the statutory auditors of the Company, who has expressed unmodified opinion.
- The Consolidated Financial Results of the Company for the quarter ended 31 March 2022 are the balancing figures between audited figures in respect of year ended 31 March 2022 and the unaudited published figures upto the nine months ended 31 December 2021 which are subjected to limited review by statutory auditors of the Company.
- The Consolidated Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- Key numbers of Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2022:

(Currency: Indian Rupees in Million)

Sr. Particulars no.	Quarter ended		Year ended	
	30.06.2022 (Unaudited)	31.03.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1. Total income from operations	860.65	1,018.80	1,076.50	4,278.11
2. Net profit before tax	119.76	199.63	249.79	1,032.66
3. Net profit after tax	85.00	188.87	239.56	959.87
4. Total comprehensive income	84.57	188.54	238.48	958.42

- The full impact of COVID-19 still remains uncertain and could be different from the estimates considered while preparing these Consolidated Financial Results. The Company will continue to closely monitor any material changes to future economic conditions.
- Details of Statement of utilization of IPO proceeds till 30 June 2022 as per Regulation 32(1) and 32(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, are as under:

(Currency: Indian Rupees in Million)

Sr. Particulars no.	*Amount of net proceeds as on 30.07.2021	Utilised amount up to 30.06.2022	Unutilised amount as at 30.06.2022
	1. Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility	1,471.00	449.72
2. Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	239.71	20.70	219.01
3. General corporate purposes	362.10	362.10	-
<b>Total</b>	<b>2,072.81</b>	<b>832.52</b>	<b>1,240.29</b>

\* The amount of net proceeds directly received in monitoring agency account maintained with ICICI Bank Limited.

The above Statement of utilization of IPO proceeds has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 July 2022 and has been certified by the statutory auditors of the Company.

Unutilised amount as at 30 June 2022 were held in monitoring agency account and in deposits with scheduled commercial banks.

- Details of net loss/ (gain) on foreign currency transaction and translation included in "other income" or "other expenses" during the period/year are as under:

(Currency: Indian Rupees in Million)

Particulars	Quarter ended		Year ended	
	30.06.2022 (Unaudited)	31.03.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
Unrealised loss/ (gain) on foreign currency transaction and translation	52.57	29.81	11.30	31.37
Realised loss/ (gain) on foreign currency transaction and translation	(2.85)	(13.96)	(21.14)	(69.78)
<b>Net loss/ (gain) on foreign currency transaction and translation</b>	<b>49.72</b>	<b>15.85</b>	<b>(9.84)</b>	<b>(38.41)</b>

- The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- The above consolidated Financial Results of the Company shall be available on Company's website www.tatvachintan.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed.
- Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors  
Tatva Chintan Pharma Chem Limited

Chintan N. Shah  
Chairman and Managing Director  
DIN : 00183618  
Place : Vadodara, Gujarat, India  
Date : 25 July 2022



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Tatva Chintan Pharma Chem Limited ("the Company") for the quarter ended 30th June 2022 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended for the purpose of filing it with the BSE Limited and the National Stock Exchange of India Limited.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes results for the quarter ended 31st March, 2022 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to third quarter of the financial year which were subjected to limited review by us.

Our conclusion on the Statement is not modified in respect of this matter.



6. Our report is intended solely for use of the management for its onward submission to the BSE Limited and National Stock Exchange of India Limited in connection with the listing of equity shares of the Company as mentioned in Para 1 above. As a result, the Statement may not be suitable for another purpose. Our report should not be used, referred to or distributed for any other purpose except with our prior consent in writing.

For NDJ & Co.,  
Chartered Accountants  
Firm's Registration Number: 136345W



CA Mitali Mehta  
Partner

Membership No. 143475

UDIN No : 22143475ANNYZD4575



Date: 25<sup>th</sup> July 2022  
Place: Surat



**Tatva Chintan Pharma Chem Limited**  
(Formerly known as Tatva Chintan Pharma Chem Private Limited)  
CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat, India – 393 002  
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com. Tel. no.: +91 75748 48533

**STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022**

(Currency: Indian Rupees in Million, except per share data)

Sr. No.	Particulars	Quarter ended		Year ended	
		30.06.2022 (Unaudited)	31.03.2022 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
	<b>Income</b>				
1	Revenue from operations	860.65	1,018.80	1,076.50	4,278.11
2	Other income	18.29	11.88	15.69	105.06
3	<b>Total income (1+2)</b>	<b>878.94</b>	<b>1,030.68</b>	<b>1,092.19</b>	<b>4,383.17</b>
	<b>Expenses</b>				
a)	Cost of materials consumed	512.65	627.61	516.60	2,544.94
b)	Purchases of stock-in-trade	-	-	-	-
c)	Changes in inventories of finished goods and work-in-progress	(91.40)	(184.25)	30.81	(580.43)
d)	Employee benefits expense	85.81	82.49	70.37	308.14
e)	Finance costs	10.17	11.81	14.39	48.32
f)	Depreciation and amortisation expense	23.33	21.47	18.98	81.80
g)	Other expenses	218.62	271.92	191.25	947.74
4	<b>Total expenses</b>	<b>759.18</b>	<b>831.05</b>	<b>842.40</b>	<b>3,350.51</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>119.76</b>	<b>199.63</b>	<b>249.79</b>	<b>1,032.66</b>
6	Exceptional items	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>119.76</b>	<b>199.63</b>	<b>249.79</b>	<b>1,032.66</b>
	<b>Tax expenses / (benefits)</b>				
	Current tax	31.03	34.99	41.70	180.08
	Deferred tax	3.73	(24.23)	(31.47)	(107.29)
8	<b>Total tax expenses</b>	<b>34.76</b>	<b>10.76</b>	<b>10.23</b>	<b>72.79</b>
9	<b>Profit for the period/year (7-8)</b>	<b>85.00</b>	<b>188.87</b>	<b>239.56</b>	<b>959.87</b>
	<b>Other comprehensive income/(expense)</b>				
	Items that will not be reclassified to profit or loss	(0.61)	(0.50)	(1.49)	(2.05)
	Income tax relating to items that will not be reclassified to profit or loss	0.18	0.17	0.41	0.60
10	<b>Other comprehensive income/(expense) for the period/year, net of tax</b>	<b>(0.43)</b>	<b>(0.33)</b>	<b>(1.08)</b>	<b>(1.45)</b>
11	<b>Total comprehensive income for the period/year (9+10)</b>	<b>84.57</b>	<b>188.54</b>	<b>238.48</b>	<b>958.42</b>
12	<b>Earnings per equity share (Face value of Rs 10/- each) (not annualised)</b>				
	- Basic	3.83	8.52	11.93	44.65
	- Diluted	3.83	8.52	11.93	44.65
13	<b>Paid - up equity share capital (Face value of Rs 10/- each)</b>	<b>221.65</b>	<b>221.65</b>	<b>200.88</b>	<b>221.65</b>
14	<b>Other equity excluding revaluation reserve</b>				<b>4,467.14</b>

See accompanying notes to the standalone financial results.







**Tatva Chintan Pharma Chem Limited**  
(Formerly known as Tatva Chintan Pharma Chem Private Limited)

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502 / 17, GIDC Estate, Ankleshwar, Bharuch, Gujarat, India - 393 002

Website : www.tatvachintan.com. E-mail : cs@tatvachintan.com. Tel. no. : +91 75748 48533

**NOTES TO STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022**

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, this Statement of Standalone Financial Results for the quarter ended 30 June 2022 ("Standalone Financial Results") of Tatva Chintan Pharma Chem Limited ("Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 25 July 2022, which has been subjected to limited review by the statutory auditors of the Company, who has expressed unmodified opinion.
- The Standalone Financial Results of the Company for the quarter ended 31 March 2022 are the balancing figures between audited figures in respect of year ended 31 March 2022 and the unaudited published figures upto the nine months ended 31 December 2021 which are subjected to limited review by statutory auditors of the Company.
- The Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- The full impact of COVID-19 still remains uncertain and could be different from the estimates considered while preparing these Standalone Financial Results. The Company will continue to closely monitor any material changes to future economic conditions.
- Details of Statement of utilization of IPO proceeds till 30 June 2022 as per Regulation 32(1) and 32(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, are as under:

(Currency: Indian Rupees in Million)				
Sr. no.	Particulars	*Amount of net proceeds as on 30.07.2021	Utilised amount up to 30.06.2022	Unutilised amount as at 30.06.2022
1.	Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility	1,471.00	449.72	1,021.28
2.	Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	239.71	20.70	219.01
3.	General corporate purposes	362.10	362.10	-
<b>Total</b>		<b>2,072.81</b>	<b>832.52</b>	<b>1,240.29</b>

\* The amount of net proceeds directly received in monitoring agency account maintained with ICICI Bank Limited.

The above Statement of utilization of IPO proceeds has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 July 2022 and has been certified by the statutory auditors of the Company.

Unutilised amount as at 30 June 2022 were held in monitoring agency account and in deposits with scheduled commercial banks.


- Details of net loss/ (gain) on foreign currency transaction and translation included in "other income" or "other expenses" during the periods/year are as under:

Particulars	(Currency: Indian Rupees in Million)			
	30.06.2022 (Unaudited)	31.03.2022 (Unaudited)	30.06.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
Unrealised loss/ (gain) on foreign currency transaction and translation	41.33	21.01	6.87	14.78
Realised loss/ (gain) on foreign currency transaction and translation	(5.09)	(14.38)	(21.27)	(70.56)
<b>Net loss / (gain) on foreign currency transaction and translation</b>	<b>36.24</b>	<b>6.63</b>	<b>(14.40)</b>	<b>(55.78)</b>

- The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- The above Standalone Financial Results of the Company shall be available on Company's website www.tatvachintan.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed.
- Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors

Tatva Chintan Pharma Chem Limited

  
Chintan N. Shah  
Chairman and Managing Director  
DIN : 00183618  
Place : Vadodara, Gujarat, India  
Date : 25 July 2022

